Targeted Therapies for Colorectal Cancer

Age: 18+

Sex: Any

Trial Phase: Phase < 1

Sponsor: M.D. Anderson Cancer Center

Disqualifiers: Pregnancy, Recent malignancies, Curative therapy intent, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Who Is on the Research Team?

Scott Kopetz, MD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults over 18 with measurable, biopsy-able metastatic colorectal cancer that's not MSI-H/pMMR. Participants must have an ECOG performance status of 0-2 and agree to use contraception if they can bear children. It excludes those who are pregnant or breastfeeding, have had certain treatments recently, or conditions that could interfere with the study.

Inclusion Criteria

My cancer is not MSI-High or has proficient MMR.

I meet the specific requirements needed to participate.

I agree to use effective birth control during and after the study due to the risk of birth defects from treatment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection and Initial Treatment

Participants undergo standard of care treatment and sample collection for biomarker analysis

Varies based on individual treatment plans

Novel Intervention Strategies

Participants receive novel intervention strategies aimed at improving progression-free survival

Until disease progression or unacceptable toxicity

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Adagrasib
• Bevacizumab
• Cetuximab
• Encorafenib
• FOLFIRI
• FOLFOX
• Panitumumab
• Sotorasib
• Trastuzumab deruxtecan
• Trifluridine/tipiracil (TAS-102)
• Tucatinib

Trial Overview

The ASCEND-CRC trial tests how well different targeted drug combinations control metastatic colorectal cancer based on individual disease characteristics. Treatments include Cetuximab, Bevacizumab, FOLFIRI/FOLFOX chemotherapy regimens, and newer drugs like Trastuzumab deruxtecan.

How Is the Trial Designed?

Group I: ASCEND-CRC Sample Collection Experimental Treatment 12 Interventions

Standard of care

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+